



# Association of High-Sensitivity C-Reactive Protein and Vitamin D with Bronchial Asthma

Ali Jihad Hemid Al-Athari<sup>1\*</sup>, Ahmed Khalid Aldhalmi<sup>2</sup>, Hayder Abdul-Amir Makki Al-Hindy<sup>3</sup>

<sup>1</sup>Department of Pharmacy, Pharmacology and Toxicology, Al-Mustaqbal University College, Hillah, Iraq; <sup>2</sup>Clinical Biochemistry, College of Pharmacy, University of Mashreq, Baghdad, Iraq; <sup>3</sup>Department of Medical Physiology, College of Pharmacy, University of Babylon, Babylon, Iraq

## Abstract

**BACKGROUND:** Bronchial asthma (BA) is a common lung illness and a significant health concern globally. Vitamin D (VitD) has immunomodulatory effect able of reducing inflammatory responses in many cells intricate in BA. VitD deficiency has been linked with much inflammation and global worsening of asthmatic patients. C-reactive protein (CRP) is elevated in primary stages of inflammation of BA and high CRP values are observed with impaired pulmonary function.

**AIM:** This study aimed to evaluate the relationship between serum levels of HSCRP and vitD in patients with asthma.

**PATIENTS AND METHODS:** This is a case-control study conducted on 127-patients with 113 (sex/aged matching) healthy control. All participants had blood analysis of HSCRP and correlated with FeNo measures. VitD Values were classified as sufficient (>30 ng/ml), insufficient (20–30 ng/ml), and deficient (<20 ng/mL) based on the preceding reference. For statistical analyses, SPSS/23-IBM had used. The outcomes had calculated at a 95% CI and had assigned as significant. The categorization accuracy of HSCRP, vitD, and FeNo measures had been investigated under the “ROC curves” for asthma prediction

**RESULTS:** Compared to the control, the mean FeNo levels were significantly higher in asthmatics (p<0.001). VitaminD levels were parallel between the study groups (p > 0.05). The mean HSCRP levels were significantly (p<0.03) higher among asthmatics. Around 40% of all participants had lower than normal levels of serum VitD and <10% only revealed deficient levels. There was a positive non-significant correlation of vitD with FeNo results (r=0.067, p=0.54) and negative non-significant (r=-0.082, p=0.086) correlation of vitD with HSCRP. ROC-curve analysis showed a significant ability (p<0.001) of FeNo to distinguish asthma, with high accuracy, sensitivity, and specificity. ROC analysis of HSCRP revealed significant ability (p<0.001), but with lower accuracy, sensitivity, and specificity to distinguish asthma patients from healthy subjects. Unlikely, VitD had a non-significant (p=0.085) and lower ability to predict asthma from healthy participants showing AUC, sensitivity, and specificity.

**CONCLUSION:** No relation or minor conflicting correlations between serum levels of vitD with asthma severity, treatment history, and inflammation (as indicated by HSCRP). Highly sensitive CRP is correlated with asthma.

**Edited by:** Ksenija Bogoeva-Kostovska  
**Citation:** Al-Athari AJH, Aldhalmi AK, Al-Hindy HAM. Association of High-Sensitivity C-Reactive Protein and Vitamin D with Bronchial Asthma. Open Access Maced J Med Sci. 2022 May 04; 10(B):931-936. <https://doi.org/10.3889/oamjms.2022.8795>  
**Keywords:** Asthma; Vitamin D; Highly-sensitive C-reactive protein; FeNo  
**\*Correspondence:** Ali Jihad Hemid Al-Athari, Department of Pharmacology and Toxicology, College of Pharmacy, University of Babylon, Babylon, Iraq. E-mail: phar.hayder.abdul@uobabylon.edu.iq  
**Received:** 28-Jan-2022  
**Revised:** 22-Apr-2022  
**Accepted:** 26-Apr-2022  
**Copyright:** © 2022 Ali Jihad Hemid Al-Athari, Ahmed Khalid Aldhalmi, Hayder Abdul-Amir Makki Al-Hindy  
**Funding:** This research did not receive any financial support  
**Competing Interests:** The authors have declared that no competing interests exist  
**Open Access:** This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)

## Introduction

Bronchial asthma (BA) is a common lung illness and a significant health concern affecting over 315 million individuals globally [1], [2], [3], [4]. It continues to be under-evaluated both in diagnoses and treatment, though the lifestyle or environmental variations are potential prominent factors. As a chronic heterogeneous disease, BA involves three main respiratory pathologies: airways hyper responsiveness (AHR), inflammation, and remodeling [5]. The response in BA implicates activation of basic cells and cells of the native and adaptive immunity. Consequently, the produced mediators give rise to inflammatory cells engagement, which eventually induces chronic inflammation [6], [7].

In current years, with the increasing knowledge of diseases, the role of vitamin D (vitD) has also been comprehensively exposed. VitD has pleiotropic effects

including bones metabolism, female reproduction, gestational outcomes, neuropsychiatry, and malignancy [8], [9], [10]. In addition, vitD had also been reported to have potential valuable impacts on inflammation and pain alleviation [5], [10], [11]. Vitamin D has a forceful immunomodulatory effect able of reducing inflammatory responses in many cells intricate in BA. Deficiency of vitD has been linked with much inflammation and global worsening of asthmatic patients [12], [13]. Hence, determining the role of vitD in asthma is vital and significant.

Preceding studies had suggested that several diseases might be accompanied by acute or chronic inflammation to some degree [14], [15], [16], [17], [18]. C-reactive protein (CRP) is produced by the liver [18], [19], [20] and had recognized as one of the best inflammatory biomarkers of the acute phase [8], [21]. Of note, CRP is elevated in primary stages of inflammation of BA [7], [8]. High serum CRP values are observed with impaired pulmonary function

and AHR. In asthma, a rapid CRP synthesis serves as a widespread scavenger particle aiding in process of phagocytosis and cellular defense mechanisms [7].

For that reason, it is sensible to explore the role of vitD in BA via its associations with CRP. This comparative study was aimed to evaluate the relationship between serum levels of CRP and vitD in patients with asthma.

## Patients and Methods

### Sample collection and study design

The study had conducted in Merjan Teaching Hospital in Babylon during the period from August to November 2020 including 127 asthmatic patients with 113 (sex/aged matching) healthy control. The age of the participants ranged from 19 to 59 years. Asthma had diagnosed and assessed by physicians at the hospital, depending on the "Global Initiative for Asthma guidelines (GINA)." Whether patients were on consistent or inconsistent asthma medications, they had grouped into treated and untreated. The FeNo results had obtained in private centers, according to the "guidelines of the American Thoracic Society (ATS)".

### Biochemical assays

Highly sensitive CRP (HSCRP) and vitD had estimated by "CALBIOTECH® ELISA kit," and correlated with FeNo measures of all participants. VitD values were classified as sufficient (>30 ng/ml), insufficient (20–30 ng/ml), and deficient (<20 ng/mL) based on preceding reference [22].

### Ethical consideration

Informed consent had acquired from each participant separately, and the entire work had agreed on by the local committee for research ethics at the local authorities.

### Statistical analysis

Statistical Package for the Social Sciences (SPSS/23-IBM) had used. The Chi-squared test had used for univariate investigation, and a t-test had completed detecting variations between the studied groups, treatment groups, and genders. The outcomes had calculated at a 95% CI and had assigned as significant for all variables. The categorization accuracy of HSCRP, vitD, and FeNo measures had been investigated under the "ROC curves" for their diagnostic fitness to decide asthma prediction.

## Results

### Basic characteristics of the studied groups

The mean age of all participants was  $34.1 \pm 6.9$  years, which was parallel in the two groups. The asthmatic patients were heavier than the control subject ( $p=0.04$ ). The male patients were fewer than females in this study ( $p=0.003$ ). The asthmatic patients were treated for an average duration of  $8.02 \pm 3.9$  years. Nearly 40% of patients were on a regular antiasthma regimen. Compared to the control group, the mean FeNo levels were significantly higher in asthmatics ( $p=0.001$ ). Vitamin D mean levels were parallel between the study groups ( $p > 0.05$ ). The mean HSCRP levels were significantly ( $p=0.03$ ) higher among asthmatics. Around 40% of all participants had lower than normal levels of serum VitD and <10% only revealed deficient levels (Table 1).

**Table 1: Basic characteristics of the studied groups**

Study parameter	Total (n=240)	Asthma group (n=127)	Healthy group (n=113)	p-value
Age (years)	$34.1 \pm 6.9$	$33.4 \pm 13.0$	$34.9 \pm 10.5$	NS
BMI ( $\text{kg}/\text{m}^2$ )	$29.9 \pm 5.4$	$30.7 \pm 5.6$	$28.8 \pm 5.0$	0.04
Sex (no %)	Males (122) Females (118)	55 (45.1%) 72 (61%)	67 (54.9%) 46 (39%)	0.003
Treatment history	On treatment Without treatment	53 (41.7%) 74 (58.3%)	0.05	
Duration of asthma (years)	$8.02 \pm 3.9$			
FENO (ppb)	$28.6 \pm 20.1$	$43.8 \pm 29.5$	$8.9 \pm 4.0$	0.001
VitD2 (ng/ml)	$19.7 \pm 6.9$	$20.4 \pm 7.0$	$18.7 \pm 6.7$	NS
Sufficient	147 (61.1%)	72 (56.9%)	75 (66.7%)	NS
Insufficient	71 (30%)	45 (35.3%)	26 (23.1%)	
Deficient	22 (8.9%)	10 (7.8%)	12 (10.3%)	
HSCRP (mg/L)	$4.7 \pm 3.8$	$5.3 \pm 8.9$	$3.3 \pm 3.5$	0.03

### Effect of asthma therapy

The effect of asthma therapy on vitD and HSCRP levels among asthmatic patients is well studied as shown in Table 2. It reveals that no effect of history of the treatment of BA on the blood levels of both variables ( $p=0.34$  and  $0.429$ ), respectively.

**Table 2: Relationship of Vitamin D2 and HSCRP with history of treatment**

	Treatment	Mean $\pm$ SD	p-value
VitD2	On	$21.9 \pm 10.9$	0.341
	With out	$20.2 \pm 5.1$	
HSCRP	On	$6.4 \pm 11.9$	0.427
	With out	$4.7 \pm 6.0$	

### Correlation of FeNo results with HSCRP and Vitamin D2

There was a positive non-significant correlation of vitD with FeNo results ( $r=0.067$ ,  $p=0.54$ ) and negative non-significant ( $r=-0.082$ ,  $p=0.086$ ) correlation of vitD with HSCRP (Table 3).

**Table 3: Correlation of FeNo results with HSCRP and Vitamin D2**

	HSCRP	VitD2
FeNo		
Correlation	0.082	0.067
Significance	0.43	0.54
HSCRP		
Correlation	-	-0.082
Significance	-	0.086

ROC curve analysis (Figure 1 and Table 4) of FeNo, vitD, and HSCRP values had performed to inspect their predictability for asthma. It showed a significant ability ( $p < 0.001$ ) of FeNo to distinguish asthma, with high accuracy, sensitivity, and specificity: 0.967, 93.5%, and 93.2%, at 95% CI [0.946-1.000], respectively. Likewise, ROC curve analysis of HSCRP revealed significant ability ( $p < 0.001$ ), but with the lower accuracy (0.881), sensitivity (87.1%), and specificity (76.3%) at 95% CI [0.812–0.950] to distinguish asthma patients from healthy subjects. Unlikely, VitD had a non-significant ( $p = 0.085$ ) and lower ability to predict asthma from healthy participants showing AUC (0.612), sensitivity (54.8%), and specificity (68.3%) at 95% CI [0.488–0.736].




Figure 1: ROC curve for predictive features of VitD, HSCRP, and FeNo for asthma diagnoses

## Discussion

In the latter decades exclusively, a cumulative bulk of data emphasized how vitD could control several biological activities; henceforth, vitD was revived being not simply the bones vitamin, but as well, multipurpose vitamin [9]. In this context, several epidemiological studies address the link between vitD and BA [5], [22], and the role of vitD insufficiency in asthma evolution and exacerbations [23].

Table 4: ROC curve for predictive features of VitD, HSCRP, and FeNo for asthma diagnoses

Variables	AUC	Significance	Specificity (%)	Sensitivity (%)	95% Confidence interval
VitD2	0.612	0.085	68.3	54.8	0.488 0.736
HSCRP	0.881	0.001	87.1	76.3	0.812 0.950
FeNo	0.975	0.001	93.2	93.5	0.946 1.000

In our group of adults with BA, no correlation between reduced vitD levels and FeNo or HSCRP levels had reported, though HSCRP levels and FeNo index were significantly higher among BA patients compared to

the control group. As well, poor ability of vitD for asthma prediction compared to FeNo and HSCRP was found. Supporting our findings, are three pieces of research had conducted on different ages; one conducted in Belgium [24], and two in the USA [25], [26], which had revealed no influential role of vitD in BA.

Our outcomes are intriguing in the context of previous Iraqi studies [27], [28], [29]. Meanwhile, Han *et al.* reported a parallel decreased prevalence of vitD insufficiency in BA in a US national study in 2017 [12]. VitD activates vitD receptor (VDR) and induces an immune modulatory effect on host immune mediators (especially defensins and cathelicidin) [30] or immune cells such as dendritic cells, macrophages, B/T lymphocytes, and besides basic respiratory cells [31].

Vitamin D status is best measured by assessing serum 25-(OH)D as it reflects the peak of all vitD metabolites and has a shelf-life of around 3 weeks [31]. Despite the fortified foods and the multivitamin intakes, few studies have exposed that vitD deficiency is still prevailing in many developing states including sunny zones. An altered lifestyle like sunlight under-exposure, change to indoor activities, sunscreen applications, besides nutritional changes are potential etiologies [32]. In this sense, the fortified foods in present dosages seem insufficient to prevent vitD deficiency. Moreover, deficient vitD levels are multifactorial that include race, gender, polymorphisms or deficient vitD binding proteins or VDRs, and other genetic factors involved in vitD breakdown [5]. Worthy to mention, that subjects with severe BA are expected to spend more hours indoors with less sun exposure, leading to lower serum Vitamin D levels.

Conversely, outcomes from interventional trials were inconsistent and there is still much disagreement as to whether or not vitD supplements present a practical substitute or adjunct therapy for BA. Another cohort had included a wide pediatric asthma group in Costa Rica, failed to display a significant inverse relation of serum vitD with AHR [33]. However, there was no standardization of asthma treatment in this survey. Moreover, a previous study assessing patients with vitD-resistant rickets exhibited protection to the airways hyper-reactivity triggered by methacholine challenge [34].

Secondary studies were piloted in two samples of adolescents in the USA in 2013 revealed a lack of association between serum 25(OH) vitD and BA [30]. In 2015, a Danish study conducted by Thuesen *et al.* shows that vitD levels do not impact the worsening of asthma and atopy among adults [35].

Maternal cord-blood levels of vitD had inverse associations with risk of respiratory infection and childhood wheezing but no association with incident asthma in the children at their later adolescent ages in New Zealand study [36].

Based on the data from the previous studies, a parallel relation between vitD and BA outcomes

could be concluded. Yet, it is confusing to express a relationship between them owing to certain limitations of these surveys including the bias of case selection, other confounders (physical activity, gender, age, and BMI), and different sample sizes. All these limitations could have produced some false relationships between vitD and BA. In addition, all these studies, not without major methodological weaknesses, which limit our sureness in their outcomes. For instance, none of the aforesaid studies applied standardized therapy to exclude treatment variations, besides no study observes seasonal variations among BA patients.

The role of inflammation in AHR is documented by numerous previous scholars [6], [7]. HSCRCP is a marker indicating low-grade inflammation [17], [20], [37]. A prior meta-analysis proposed that vitD supplements reduce serum HSCRCP concentrations in adults by 1mg/l or more [38]. An anti-inflammatory impact of vitD is a consistent opinion in studies of cell lines and human-derived mononuclear cells [39]. Because vitD might reduce the systemic inflammatory response and protect from BA, this study aimed to evaluate the prevalence of vitD insufficiency with HSCRCP among asthmatic patients.

What is more, transforming growth factor- $\beta$  (TGF $\beta$ ) is a pleiotropic-cytokine [40], [41], [42], formed by epithelial respiratory cells and excites fibroblasts growing that may induce excessive fibrosis of pulmonary soft tissue [3]. Prior reviews verified a raised TGF $\beta$ 1 in obstructing lung illnesses. In addition, both IL-1B and TGF $\beta$  adjust T-helper17 cells, which have a serious role in the etiopathology of chronic inflammation. As well, both interleukins and TGF $\beta$  can activate platelet derived growth factor (PDGF) release [2], [43]. PDGF is a strong mitogen released by diverse cells like fibroblasts (40) identified to induce an immune-regulatory influence in BA by facilitating remodeling of respiratory airways [2].

The data from this study finding are consistent with the outcomes reported currently [7], [8], which showed a significant correlation of HSCRCP with the severity of BA. Interleukins (1 and 6) modify HSCRCP and take apart in airway inflammation. High serum HSCRCP values are linked with impaired respiratory functions and AHR. In BA, there is a rapid CRP synthesis that serves as a universal hunter particle aiding in processes of opsonization, phagocytosis, and cytotoxicity [7], [44].

In line with the previous studies [8], [45], we found that among asthmatic patients, the levels of vitD in the serum were not associated that of HSCRCP. Likewise, an Australian randomized trial of 413 subjects indicated that the relation of CRP with vitD was not significant (46). Earlier reports from tertiary referral centers validated increased serum HSCRCP values accompanied asthma exacerbation [7], [8], [44]. Limited revisions concentrated on the non-linear relations between vitD and CRP, and vitD was usually categorized as deficient or not [8], [46]. Yet, the categorical parameter cannot

mirror the global distribution of vitD, and cannot fully reveal the associations of HSCRCP with vitD.

In BA, and principally in the severe form, several biomarkers have been deliberated; nevertheless, the only restricted number so far can be simply practiced on a clinical base. Unfortunate speaking, currently, an ideal model does not present and there is a real overlay among the biomarkers.

## Conclusion

No relation or minor conflicting correlations between serum levels of vitD with asthma severity, treatment history, and inflammation (as indicated by HSCRCP). Highly sensitive CRP is correlated with asthma. High-quality extended studies are desirable to reliably answer the inquiry of concern.

### Limitation

There were a few limitations in this study. The sample size was small as well as it was not a longitudinal study. All of the asthmatic cases should be evaluated for the control of asthma by using ACT or ACQF according to GINA guidelines. PFT should be used also.

## References

1. Abbas AH, Khadim HW, Jasim AH, Al-Hindy HA, Hammoud SS. Early detection and diagnosis of chronic obstructive pulmonary disease in asymptomatic male smokers and ex-smokers using spirometry. *Rev Latinoam Hipertension*. 2021;15(1):44-50.
2. HA Makki, Hemid Al-Athari AJ, Mousa MJ, Hameed SJ, SH Obeed. The utility of serum IL-1 $\beta$  and CRP together with fractional exhaled nitric oxide in the diagnosis of asthma in adults. *Neuroquantology*. 2021;19(8):119-24.
3. Abbas AH, MA Rasheed, Al-Hindy HA, Mousa MJ, Al-Shalah HA. The role of serum IL-1 $\beta$  in combination with fractional exhaled nitric oxide in the diagnosis of adult bronchial asthma. *Neuroquantology*. 2021;19(9):13-9.
4. Amjed H, Makki HA, Shahlaa KH, Mazin J. Conicity index as an anthropometric index of central obesity in the prediction of adult bronchial asthma; correlation with fractional exhaled nitrous oxide tests. *Medico Legal Update*. 2021;2(2):7.
5. Hall SC, Fischer KD, Agrawal DK. The impact of vitamin D on asthmatic human airway smooth muscle. *Expert Rev Respir Med*. 2016;10(2):127-35. <https://doi.org/10.1586/17476348.2016.1128326>  
PMid:26634624
6. Hall S, Agrawal DK. Key mediators in the immunopathogenesis of allergic asthma. *Int Immunopharmacol*. 2014;23(1):316-29. <https://doi.org/10.1016/j.intimp.2014.05.034>  
PMid:24933589
7. Qasim J, Saad H, Ghada H, Hayder AA. High-sensitivity C-reactive protein assessment in bronchial asthma: Impact of

- exhaled nitric oxide and body mass index. *Syst Rev Pharm.* 2020;11(3):705-11.
8. Yang F, Sun M, Sun C, Li J, Yang X, Bi C, *et al.* Associations of C-reactive protein with 25-hydroxyvitamin D in 24 specific diseases: A cross-sectional study from NHANES. *Sci Rep.* 2020;10:5883. <https://doi.org/10.1038/s41598-020-62754-w> PMID:32246038
  9. Marazziti D, Parra E, Palermo S, Barberi FM, Buccianelli B, Ricciardulli S, *et al.* Vitamin D: A pleiotropic hormone with possible psychotropic activities. *Curr Med Chem.* 2021;28(19):3843-64. <https://doi.org/10.2174/0929867328666201210104701> PMID:33302828
  10. Alhaideri AF, Waleed AA, Mohammed Al-Agam AN, Alzughaihi MA, Al-Hindy HA, Mazin J. Mousa hypovitaminosis D is a biological vulnerability for depressive symptoms in major depression at the era of COVID-19 outbreak. *Clin Schizophr Relat Psychoses.* 2022;16(5):In press.
  11. Rai V, Dietz NE, Dilisio MF, Radwan MM, Agrawal DK. Vitamin D attenuates inflammation, fatty infiltration, and cartilage loss in the knee of hyperlipidemic mice. *Arthritis Res Ther.* 2016;18:203. <https://doi.org/10.1186/s13075-016-1099-6> PMID:27624724
  12. Han YY, Forno E, Celedón JC. Vitamin D insufficiency and asthma in a US nationwide study. *J Allergy Clin Immunol Pract.* 2017;5(3):790-6.e1. <https://doi.org/10.1016/j.jaip.2016.10.013> PMID:27913247
  13. Alzughaihi MA, Nassar A, Shumran AM, Makki Al-Hindy HA, Al-Dahmashi HO, Al-Khafaji NS, *et al.* The association of serum 1, 25-dihydroxy vitamin D2 status with asthma in a comparative study of Iraqi adults. *Biochem Cellular Arch.* 2022;22(2):In Press.
  14. Guo H, Callaway JB, Ting JP. Inflammation: Mechanism of action, role in disease, and therapeutics. *Nat Med.* 2015;21:677-87. <https://doi.org/10.1038/nm.3893> PMID:26121197
  15. Abdul-Hussein HK, Fouad S, Al-Aaraji AJ, Makki Al-Hindy HA, Mousa MJ. Biochemical causal-effect of circulatory uric acid, and HSCRP and their diagnostic correlation in admitted patients with ischemic heart diseases. *J Cardiovasc Dis Res.* 2020;11(2):25-31.
  16. Raghdan Z, Asseel K, Dleikh F, Al-Hindy H. Is there any association between highly sensitive C-reactive protein and dental-status in ischemic heart diseases? A comparative study. *Biochem Cellular Arch.* 2020;20(2):6069-75.
  17. Al-Mumin A, Al-Hindy HA, Mazin JM. Combined assessments of multi-panel biomarkers for diagnostic performance in coronary artery disease: Case-control analysis. *Syst Rev Pharm.* 2020;11(6):7.
  18. Yesar MH, Al-Shamma AA, Al-Hindy HA. Caries burden is associated with serum uric acid and CRP in patients treated for acute coronary syndrome. *J Chem Health Risks.* 2022;12(2):In Press.
  19. Maki Al-Hindi HA, Mazin J, Jaber Al-kashwan TA, Sudan A, Abdul-Razzaq SA. On admission levels of high sensitive C-reactive protein as a biomarker in acute myocardial infarction: A case-control study. *Indian J Public Health Res Dev.* 2019;10(4):5.
  20. Asseel K, Shaker RA, Jasim R, Makki Al-Hindy HA. Biochemical significance of cystatin-C and high sensitive CRP in patients with acute coronary syndrome; any clinical correlation with diagnosis and ejection fraction. *Syst Rev Pharm.* 2020;11(3):8.
  21. Samer MM, Aliaa S, Hayder AA, Mazin JM. C-reactive protein is associated with the severity of periodontal disease — An observational study among acute myocardial infarction patients. *Syst Rev Pharm.* 2020;11(10):252-7.
  22. Searing DA, Zhang Y, Murphy JR, Hauk PJ, Goleva E, Leung DY. Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid use. *J Allergy Clin Immunol.* 2010;125(5):995-1000. <https://doi.org/10.1016/j.jaci.2010.03.008> PMID:20381849
  23. Brehm JM, Schuemann B, Fuhlbrigge AL, Hollis BW, Strunk RC, Zeiger RS, *et al.* Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. *J Allergy Clin Immunol.* 2010;126(1):52-8.e5. <https://doi.org/10.1016/j.jaci.2010.03.043> PMID:20538327
  24. Dabbah H, Bar Yoseph R, Livnat G, Hakim F, Bentur L. Bronchial reactivity, inflammatory and allergic parameters, and vitamin D levels in children with asthma. *Respir Care.* 2015;60(8):1157-63. <https://doi.org/10.4187/respcare.03763> PMID:25899478
  25. Weiss ST, Litonjua AA. Vitamin D, the gut microbiome, and the hygiene hypothesis. How does asthma begin? *Am J Respir Crit Care Med.* 2015;191(5):492-3. <https://doi.org/10.1164/rccm.201501-0117ED> PMID:25723818
  26. Jiao J, Castro M. Vitamin D and asthma: Current perspectives. *Curr Opin Allergy Clin Immunol.* 2015;15(4):375-82. <https://doi.org/10.1097/ACI.000000000000187> PMID:26106827
  27. Alqaraghuli HM. Vitamin D and its association with the severity and/or the control of asthma among adult Iraqi asthmatics. *Medico Legal Update.* 2020;20(1):655-60.
  28. Al-Sharifi ZA, Hayder A, Mahmood HG, Turki KM, Al-Karkhi II. Lack of vitamin D in Iraqi children with asthma. *Biomed Pharmacol J.* 2017;10(1):89-93.
  29. Sura O, Muhsin JM. Serum vitamin-D levels in bronchial asthmatic patients in Baghdad City. *Indian J Public Health Res Dev.* 2019;10(8):2212-7.
  30. Gergen PJ, Teach SJ, Mitchell HE, Freishtat RF, Calatroni A, Matsui E, *et al.* Lack of a relation between serum 25-hydroxyvitamin D concentrations and asthma in adolescents. *Am J Clin Nutr.* 2013;97(6):1228-34. <https://doi.org/10.3945/ajcn.112.046961> PMID:23595876
  31. Hall SC, Agrawal DK. Vitamin D and bronchial asthma: An overview of data from the past 5 years. *Clin Ther.* 2017;39(5):917-29.
  32. Thacher TD, Bart C. Vitamin D insufficiency. *Mayo Clin Proc.* 2011;86(1):50-60. <https://doi.org/10.4065/mcp.2010.0567> PMID:21193656
  33. Brehm JM, Celedón JC, Soto-Quiros ME, Avila L, Hunninghake GM, Forno E, *et al.* Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica. *Am J Respir Crit Care Med.* 2009;179(9):765-71. <https://doi.org/10.1164/rccm.200808-1361OC> PMID:19179486
  34. Bar Yoseph RB, Goldbart A, Livnat G, Hakim F, Weisman Y, Tiosano D. A mutated vitamin D receptor in hereditary vitamin D-resistant rickets prevents induction of bronchial hyperreactivity and inflammation. *J Clin Endocrinol Metab.* 2014;99(9):E1610-6. <https://doi.org/10.1210/jc.2014-1396> PMID:24885630
  35. Thuesen BH, Skaaby T, Husemoen LL, Fenger M, Jørgensen T, Linneberg A. The association of serum 25-OH vitamin D with atopy, asthma, and lung function in a prospective study of Danish adults. *Clin Exp Allergy.* 2015;45(1):265-72. <https://doi.org/10.1111/cea.12299> PMID:24575884
  36. Camargo CA Jr., Ingham T, Wickens K, Thadhani R, Silvers KM, Epton MJ, *et al.* Cord-blood 25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. *Pediatrics.*

- 2011;127(1):e180-7. <https://doi.org/10.1542/peds.2010-0442>  
PMid:21187313
37. Al-Agam AN, Obeiad AW, Alzughairi MA, Al-Hindy HA, Alhaider AF. The association of depressive symptoms with plasma C-reactive protein in patients with major depressive disorder under treatment %. *J Iran Rehabil J.* 2021;19(4):425-32.
38. Chen N, Wan Z, Han SF, Li BY, Zhang ZL, Qin LQ. Effect of vitamin D supplementation on the level of circulating high-sensitivity C-reactive protein: A meta-analysis of randomized controlled trials. *Nutrients.* 2014;6(6):2206-16. <https://doi.org/10.3390/nu6062206>  
PMid:24918698
39. Emily K, Calton KN, Newsholme P, Soares MJ. The impact of vitamin D levels on inflammatory status: A systematic review of immune cell studies. *PLoS One.* 2015;10(11):e0141770. <https://doi.org/10.1371/journal.pone.0141770>  
PMid:26528817
40. Fouad Shareef Dleikh AJ, Mohin R, Mousa MJ, Makki Al-Hindy HA, Abd Al-Ka'abi B. Possible cause-and-effect linkage of transforming growth factor-beta1 and platelets derived growth factor-AB with delayed anthropometric parameters in adolescent patients with Cooley's anemia: Cases vis control research strategy. *Eur Asian J Bio Sci.* 2020;14(1):7.
41. Hayder AA, Al-Hindy MJ, Al-Saad RZ, Widad HD. Relationship of levels of transforming growth factorbeta1 (TGF- $\beta$ 1) to the levels of ferritin in blood of transfusion dependent  $\beta$ -thalassemia major patients with growth retardation: A case-control study. *Eur Asian J Biosci.* 2020;14(1):521-52.
42. Mousa MJ, Sabeeh H, Maki Al-Hindy AA. Low level laser (Biophotomodulation) therapy for the treatment of diabetic foot ulcers with 532 nm KTP laser induces wound healing, fibroblast proliferation and over-expression of TGF. *Sys Rev Pharm.* 2020;11(6):396-403.
43. Bash HS, Al-Hindy HA, Al-Mamory BH, Mazin JM. The study of serum ferritin level as a predictor of growth retardation in thalassemia-major. *Arch Venez Farmacol Ter.* 2021;40(5):492-7.
44. Qian FH, Zhang Q, Zhou LF, Liu H, Huang M, Zhang XL, *et al.* High-sensitivity C-reactive protein: A predicative marker in severe asthma. *Respirology (Carlton, Vic).* 2008;13(5):664-9. <https://doi.org/10.1111/j.1440-1843.2008.01314.x>  
PMid:18513241
45. Määttä AM, Kotaniemi-Syrjänen A, Malmström K, Malmberg LP, Sundvall J, Pelkonen AS, *et al.* Vitamin D, high-sensitivity C-reactive protein, and airway hyperresponsiveness in infants with recurrent respiratory symptoms. *Ann Allergy Asthma Immunol.* 2017;119(3):227-31. <https://doi.org/10.1016/j.anai.2017.06.014>  
PMid:28757230
46. Zheng S, Wang B, Han W, Zhu Z, Wang X, Jin X, *et al.* Vitamin D supplementation and inflammatory and metabolic biomarkers in patients with knee osteoarthritis: *Post hoc* analysis of a randomised controlled trial-corrigendum. *Br J Nutr.* 2019;121(1):118-9. <https://doi.org/10.1017/S0007114518002702>  
PMid:30430951